Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,487 | -165,297 | -154,073 | -143,219 | -12,019 |
| Depreciation Amortization | 79 | 290 | 227 | 155 | 72 |
| Accounts receivable | -46 | 425 | 421 | 431 | -614 |
| Accounts payable and accrued liabilities | 70 | -1,852 | -194 | 23 | -100 |
| Other Working Capital | -2,453 | -20,917 | -16,511 | -11,295 | -6,228 |
| Other Operating Activity | 3,560 | 129,026 | 124,869 | 122,753 | 2,810 |
| Operating Cash Flow | $-14,277 | $-58,325 | $-45,261 | $-31,152 | $-16,079 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -358 | -551 | -469 | -257 | -157 |
| Investing Cash Flow | $-358 | $-551 | $-469 | $-257 | $-157 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 29 | 714 | 551 | 551 | 367 |
| Common Stock Repurchased | N/A | -1,502 | -855 | -855 | -2 |
| Financing Cash Flow | $29 | $-788 | $-304 | $-304 | $365 |
| Beginning Cash Position | 81,441 | 140,717 | 140,717 | 140,717 | 140,717 |
| End Cash Position | 66,835 | 81,441 | 94,683 | 109,004 | 124,846 |
| Net Cash Flow | $-14,606 | $-59,664 | $-46,034 | $-31,713 | $-15,871 |
| Free Cash Flow | |||||
| Operating Cash Flow | -14,277 | -58,325 | -45,261 | -31,152 | -16,079 |
| Capital Expenditure | -358 | -551 | -469 | -257 | -157 |
| Free Cash Flow | -14,635 | -58,876 | -45,730 | -31,409 | -16,236 |